Back to catalogue
№ 369 33 filings · 2021-11-24 → 2026-06-29

WYNNSTAY GROUP PLC

WYN
Food, Beverage and Tobacco Share price 361p Market cap £83m Overall fit 260 /1000

Well-managed, cheap-ish UK ag-inputs microcap with a fortress balance sheet, but essentially zero AI-receiver exposure, only modest operating leverage and only fair valuation. Solid quality but a poor fit for a portfolio built around AI beneficiaries with long-tail upside.

Fair value range 340p–470p Mid case · £93m
Absolute upside +12% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean audited financials with unqualified opinions and clear net cash position
  • H1 2026 run-rate provides visibility into FY26 earnings
  • Multiple valuation methods (forward P/E, EV/EBIT, P/B) converge on similar range
Limits the call
  • Glasson fertiliser stock realisations can move adjusted profit £1-2m in either direction
  • Open HSE fatality investigation is an unquantified tail-risk with no provision recognised
Methodology

Blended forward P/E (11-13x) and EV/EBIT (7-9x) on normalised earnings

In one line · bull case

Genesis-driven margin recovery at a cash-rich, dividend-compounding UK ag-inputs microcap trading at ~10-11x forward earnings and ~0.65x book.

In one line · biggest risk

Commodity-driven fertiliser stock realisations and the unquantified HSE fatality investigation could each materially disrupt the reported earnings trajectory.

Drivers
AI beneficiary 8 /100
No exposure to AI value chain; internal IT investment does not generate AI-driven revenue or expanded TAM.
Operating leverage 32 /100
Distribution-plus-blending model with ~86% variable cost of sales; Project Genesis has removed some fixed cost but incremental margin remains modest.
Earnings vs expectations 50 /100
Mixed track record: FY22 beat, FY23 and FY24 profit warnings, FY25 beat, H1 2026 in line — no clear pattern.
Growth momentum 55 /100
Adjusted PBT +21% FY25, +12% H1 2026; revenue flat to modestly down; Strategy Genesis targets 160k tonnes new capacity over 5 years.
Moat 38 /100
Established brand, 51-store rural network, second-largest UK fertiliser blender via Glasson — real but modest scale advantage in a fragmented sector.
Earnings quality 58 /100
Multiple adjustments to reach adjusted profit (£5.9m non-recurring FY25); working capital swings large; cash conversion decent through the cycle.
Management quality 62 /100
New CEO Alk Brand (Oct 2024) has executed a credible turnaround; 22 years of unbroken dividend growth; recent Chair succession orderly.
Cyclicality 55 /100
Agricultural commodity and weather exposure creates lumpy earnings; partially defensive as inputs to food production.
Leverage 12 /100
Net cash £10.9m (ex-IFRS 16) at H1 2026, undrawn £10m RCF; genuine fortress balance sheet.
Value-trap signals · 4
  • Structurally low ROCE (~7% FY25)
  • Repeated commodity-driven earnings adjustments and one-offs
  • Open HSE fatality investigation with no provision recognised
  • UK farm subsidy transition (BPS to ELMS/SFS) creates persistent customer uncertainty

WYNNSTAY GROUP PLC (WYN) — Investment Research Note

Executive summary

Wynnstay is a c.108-year-old UK agricultural inputs distributor operating three segments — Feed & Grain, Arable (fertiliser/seed) and Stores (51 rural retail outlets) — supplying livestock and arable farmers across England and Wales. Across the period covered, the group navigated commodity-price volatility, a very poor 2024 harvest, an HSE fatality (Jan 2025), a full management refresh under new CEO Alk Brand and a "Project Genesis" restructuring that has moved adjusted PBT from £7.6m (FY24) → £9.2m (FY25) → guided further improvement in FY26 (H1 2026 adj PBT +11.7% at £6.0m). The single most important point for valuation today is that Genesis-driven margin recovery is real but the underlying business remains a low-margin (≈1.6% adj operating margin), commodity-linked distribution/blending model — so valuation must be anchored to modest, cyclically-adjusted earnings, not to Project Genesis best-case outcomes.

Fair value estimate

  • Fair value range: 340p – 470p per share → implied market cap £78m – £108m.
  • Methodology: blend of forward P/E on normalised earnings and a sanity-check EV/EBIT multiple. Central case assumes FY26 adjusted EPS of ~32–35p (H1 alone was 20.9p, guidance is "further improvement on FY25's 28.8p", tempered by seasonal H2 softness in Stores and commodity risk); applying 11–13x forward P/E for a sub-scale, low-margin UK Consumer Staples microcap yields ~350p–450p, plus ~£11m net cash (≈47p/share) adds a small cushion. EV/EBIT of 7–9x on £9.5–10m adjusted EBIT corroborates.
  • Latest disclosed market cap £86.3m (375p). Fair value midpoint ≈ 405p implies ~8% upside (range: –9% to +25%). The stock is broadly fair-value, tilting slightly cheap.

Sector context

Confirmed: Consumer Staples / Food, Beverage & Tobacco (ICB) — though functionally an agricultural supplies distributor, not a food producer. Quality profile is in line with UK ag-inputs peers: low structural margin, seasonal working capital, net-cash balance sheet, long dividend history. Listed peers: NWF Group (NWF.L) (food/fuel/feed distribution, very similar profile), Anpario (ANP.L) (animal feed additives, higher margin), and Carr's Group (CARR.L) (agriculture and engineering). Wynnstay sits between NWF (larger, more diversified) and Carr's on scale.

Investment thesis

  1. Project Genesis is delivering measurable operating improvement, not just narrative. Adjusted PBT H1 2026 £6.0m is +59% vs H1 2024 (£3.8m) on essentially flat revenue, driven by site closures (Glasson Dock, Standon), unified GrainLink trading and Avonmouth fertiliser blending coming online 2026-06 interim. Management guided "no further material restructuring charges in FY26" 2026-02 final.
  2. Fortress balance sheet with 22 years of unbroken dividend growth. Net cash (ex-IFRS 16) £10.9m at H1 2026, undrawn £10m RCF, dividend cover ~2x, 4.7% trailing yield at 375p; genuine downside protection 2026-06 interim, 2026-02 final.
  3. Modest current valuation with structural transition tailwind. Trades at ~10–11x forward earnings, ~0.65x net book value, EV/EBIT ~8x — undemanding for a business with visible earnings recovery, new manufacturing capacity (Carmarthen +20k tonnes, Avonmouth) and a targeted 160k tonnes of incremental capacity over the Strategy Genesis five-year plan 2026-02 final.

Key risks

  1. HSE fatality investigation remains open with no provision recognised. A colleague died at Llansantffraid in Jan 2025; directors state they cannot reliably estimate financial impact, so no provision is in the accounts — an unquantified but potentially material liability 2026-06 interim, 2026-02 final.
  2. Structural exposure to UK farming policy and commodity volatility. The Basic Payment Scheme wind-down and transition to ELMS/SFS create farmer uncertainty; commodity swings hit fertiliser stock realisations (FY24 Glasson underperformance, FY22 windfall gains, FY23 unwind) — earnings are inherently lumpy 2024-10 trading update, 2023-11 trading update, 2022-05 trading update.
  3. Very thin margins with limited pricing power. FY25 gross margin ~13.8%, adjusted operating margin ~1.6% — any incremental cost inflation in labour, logistics or energy (all called out repeatedly) directly compresses profit; Stores segment H1 2026 PBT fell to £2.0m from £3.1m on cost pressures 2026-06 interim.

Operating leverage

Modest and asymmetric. Wynnstay is a distribution-plus-blending business, not a fixed-cost software or scale industrial. Cost of sales is ~86% of revenue (FY25: £502.9m/£583.4m), meaning ~86p of every incremental £1 of revenue is variable input cost. Manufacturing/distribution/selling costs (£60.8m FY25) and admin (£10.9m) provide some fixed base, but bagged feed volumes, fertiliser tonnage and grain trading margins are largely price-taker with pass-through pricing. On the basis that ~£72m of the cost stack is fixed-ish, a 10% revenue beat (assuming margin structure holds) would add perhaps £1.2–1.5m to operating profit — meaningful (~15% of adj EBIT) but nothing like the multiples-of-profit outcomes the investor is looking for. The exception is Glasson fertiliser blending, where stock positions can generate one-off windfalls (2022) or losses (2023) in the £1–2m range on commodity moves — a form of leverage, but to the wrong variable. Project Genesis has removed some fixed cost via site closures, so the operating leverage is improving at the margin, but the model is fundamentally not high-leverage 2026-02 final, 2026-06 interim.

Value-trap signals

  • Structurally low ROCE (~7% at group level in FY25, up from 5.6% FY24) — capital-intensive with limited pricing power.
  • Repeated commodity-related profit adjustments and one-offs make "clean" earnings hard to identify.
  • Open HSE fatality investigation with no provision.
  • UK farm-sector transition (BPS → ELMS/SFS) creates persistent customer uncertainty.
  • Book value has drifted down slightly (FY24: £134.8m → FY25: £132.8m) despite retained earnings, reflecting dividend outflow exceeding statutory earnings after non-recurring items.
  • However, 22 years of dividend growth, net cash balance sheet and a credible turnaround underway argue against classifying this as a value trap. It is more a "grinder" than a trap.

Earnings vs. expectations

  • FY22 (final): Record £22.6m underlying PBT, driven by one-off Glasson fertiliser stock gains — materially ahead of original expectations (Aug 2022 trading update pre-flagged) 2023-01 final, 2022-08 trading update.
  • FY23 (final): £9.2m adjusted PBT — miss vs consensus after a weak Q4 arable season and Glasson stock reversal; Nov 2023 profit warning 2024-01 final, 2023-11 trading update.
  • FY24 (final): £7.6m adjusted PBT — miss vs original expectations (Oct 2024 profit warning); Humphrey acquisition and Glasson blend margins underperformed 2025-02 final, 2024-10 trading update.
  • FY25 (final): £9.2m adjusted PBT vs Factset consensus £8.5m — beat, driven by Project Genesis 2026-02 final, 2025-12 trading update.
  • H1 2026 (interim): adj PBT £6.0m, +11.7% YoY, in line with expectations with confidence in full-year guidance 2026-06 interim.
  • Pattern: mixed — two large misses in FY23 and FY24 followed by two beats in FY22 and FY25. Not a consistent beat/miss track record; earnings visibility remains limited by commodity/weather variables.

Conviction

Conviction: 3 (moderate). The valuation call is a fair-with-modest-upside conclusion that I hold with reasonable confidence. Anchoring factors: (i) audited financials are clean with unqualified opinions, (ii) balance sheet position is unambiguous (net cash), (iii) forward earnings can be sanity-checked against H1 2026 disclosed run-rate. Limiting factors: (i) commodity-driven stock realisations at Glasson can move adjusted profit by £1–2m in either direction and are inherently hard to forecast, (ii) the HSE investigation is an unquantified tail risk.

Driver scoring rationale (see JSON below)

The investor profile calls for AI-receiver exposure, operating leverage and valuation discipline. Wynnstay scores strongly on balance sheet quality and valuation discipline, weakly on operating leverage, and essentially zero on AI beneficiary status. Overall this is a well-run, cheap-ish, quality-defensive UK microcap — but it is completely outside the investor's stated strategy focus.

Filings consulted · 36

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-06-29Interim Results2026-06-29_9640356_interim-results.md0.90
  2. 2026-06-10Notice OF HY Results Amp Investor Presentation2026-06-10_9610080_notice-of-hy-results-amp-investor-presentation.md0.70
  3. 2026-03-24Result OF Agm2026-03-24_9490080_result-of-agm.md0.30
  4. 2026-03-24Agm Statement2026-03-24_9487870_agm-statement.md0.40
  5. 2026-02-09Final Results2026-02-09_9419950_final-results.md1.00
  6. 2026-01-26Notice OF Results And Investor Presentation2026-01-26_9385686_notice-of-results-and-investor-presentation.md0.59
  7. 2025-12-01Trading Update2025-12-01_9265973_trading-update.md0.72
  8. 2025-07-01Interim Results2025-07-01_8955913_interim-results.md0.58
  9. 2025-03-27Result OF Agm2025-03-27_8801427_result-of-agm.md0.20
  10. 2025-02-11Final Results2025-02-11_8730271_final-results.md0.65
  11. 2025-02-11Correction OF Record Date For Final Dividend2025-02-11_8732037_correction-of-record-date-for-final-dividend.md0.20
  12. 2025-01-21Notice OF Final Results2025-01-21_8697853_notice-of-final-results.md0.65
  13. 2024-10-02Trading Update2024-10-02_8455711_trading-update.md0.55
  14. 2024-06-25Interim Results2024-06-25_8275722_interim-results.md0.41
  15. 2024-03-26Result OF Agm2024-03-26_8108122_result-of-agm.md0.14
  16. 2024-03-26Agm Statement2024-03-26_8106112_agm-statement.md0.18
  17. 2024-02-01Investor Presentation2024-02-01_8016325_investor-presentation.md0.32
  18. 2024-01-30Final Results2024-01-30_8011684_final-results.md0.45
  19. 2023-11-30Trading Update2023-11-30_7911569_trading-update.md0.38
  20. 2023-07-03Interim Results2023-07-03_7608312_interim-results.md0.23
  21. 2023-03-22Result OF Agm2023-03-22_7276373_result-of-agm.md0.07
  22. 2023-03-21Agm Statement2023-03-21_7479725_agm-statement.md0.10
  23. 2023-02-01Final Results2023-02-01_7290827_final-results.md0.25
  24. 2023-01-30Full Year Results Presentation2023-01-30_7232944_full-year-results-presentation.md0.25
  25. 2022-11-17Acquisition OF Tamar Milling Limited2022-11-17_7411977_acquisition-of-tamar-milling-limited.md0.19
  26. 2022-11-14Trading Update2022-11-14_7370246_trading-update.md0.21
  27. 2022-09-06Trading Update2022-09-06_7211589_trading-update.md0.21
  28. 2022-08-17Proposed Equity Placing OF C 10 5M2022-08-17_7129504_proposed-equity-placing-of-c-10-5m.md0.17
  29. 2022-06-28Interim Results2022-06-28_7115179_interim-results.md0.23
  30. 2022-05-04Trading Update2022-05-04_7145572_trading-update.md0.21
  31. 2022-03-23Result OF Agm2022-03-23_7049162_result-of-agm.md0.07
  32. 2022-03-22Agm Statement2022-03-22_7004118_agm-statement.md0.10
  33. 2022-03-10Acquisition2022-03-10_6845122_acquisition.md0.19
  34. 2022-02-02Investor Presentation2022-02-02_6705935_investor-presentation.md0.17
  35. 2022-02-02Final Results2022-02-02_6705883_final-results.md0.25
  36. 2021-11-24Trading Update2021-11-24_6839267_trading-update.md0.21

This research note was authored by a large language model after reading 33 regulatory filings published between 2021-11-24 and 2026-06-29. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.